Sitravatinib/Ipi/Niv as first line treatment for advanced RCC
Qian Janie Qin, Assistant Professor at UT Southwestern Medical Center, shared a recent article by Jose A. Karam on X:
“Dr. Pavlos Msaouel discussing Sitravatinib/Ipi/Niv in 1L advanced RCC- efficacy seen, however significant toxicity.
Tumor cell-spc transcriptomic signature identified& may link to resistance.
Role of triplet treatment remains to be defined, and deep dive correlatives may offer insights.”
Authors: Jose A. Karam, Pavlos Msaouel, Cara L. Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Y. Shah, Ignacio I. Wistuba, Enrica Marmonti, Dzifa Y. Duose, Edwin R. Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D. Chin, Peter Olson, Hirak Der-Torossian, Xiaohong Yan, Nizar M. Tannir and Christopher G. Wood
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023